Literature DB >> 29659842

Insights into the pathogenesis of dominant retinitis pigmentosa associated with a D477G mutation in RPE65.

Elliot H Choi1, Susie Suh1, Christopher L Sander1, Christian J Ortiz Hernandez1,2, Elizabeth R Bulman1,3, Nimesh Khadka1, Zhiqian Dong1,4, Wuxian Shi5, Krzysztof Palczewski1,6, Philip D Kiser1,3,6.   

Abstract

RPE65 is the essential trans-cis isomerase of the classical retinoid (visual) cycle. Mutations in RPE65 give rise to severe retinal dystrophies, most of which are associated with loss of protein function and recessive inheritance. The only known exception is a c.1430G>A (D477G) mutation that gives rise to dominant retinitis pigmentosa with delayed onset and choroidal and macular involvement. Position 477 is distant from functionally critical regions of RPE65. Hence, the mechanism of D477G pathogenicity remains unclear, although protein misfolding and aggregation mechanisms have been suggested. We characterized a D477G knock-in mouse model which exhibited mild age-dependent changes in retinal structure and function. Immunoblot analysis of protein extracts from the eyes of these knock-in mice demonstrated the presence of ubiquitinated RPE65 and reduced RPE65 expression. We observed an accumulation of retinyl esters in the knock-in mice as well as a delay in rhodopsin regeneration kinetics and diminished electroretinography responses, indicative of RPE65 functional impairment induced by the D477G mutation in vivo. However, a cell line expressing D477G RPE65 revealed protein expression levels, cellular localization and retinoid isomerase activity comparable to cells expressing wild-type protein. Structural analysis of an RPE65 chimera suggested that the D477G mutation does not perturb protein folding or tertiary structure. Instead, the mutation generates an aggregation-prone surface that could induce cellular toxicity through abnormal complex formation as suggested by crystal packing analysis. These results indicate that a toxic gain-of-function induced by the D477G RPE65 substitution may play a role in the pathogenesis of this form of dominant retinitis pigmentosa.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29659842      PMCID: PMC6005012          DOI: 10.1093/hmg/ddy128

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  71 in total

1.  RPE65 is the isomerohydrolase in the retinoid visual cycle.

Authors:  Gennadiy Moiseyev; Ying Chen; Yusuke Takahashi; Bill X Wu; Jian-Xing Ma
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-22       Impact factor: 11.205

2.  Two point mutations of RPE65 from patients with retinal dystrophies decrease the stability of RPE65 protein and abolish its isomerohydrolase activity.

Authors:  Yusuke Takahashi; Ying Chen; Gennadiy Moiseyev; Jian-xing Ma
Journal:  J Biol Chem       Date:  2006-06-05       Impact factor: 5.157

Review 3.  Review and update on the molecular basis of Leber congenital amaurosis.

Authors:  Oscar Francisco Chacon-Camacho; Juan Carlos Zenteno
Journal:  World J Clin Cases       Date:  2015-02-16       Impact factor: 1.337

4.  Mutations in the RPE65 gene in patients with autosomal recessive retinitis pigmentosa or leber congenital amaurosis.

Authors:  H Morimura; G A Fishman; S A Grover; A B Fulton; E L Berson; T P Dryja
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-17       Impact factor: 11.205

5.  Features and development of Coot.

Authors:  P Emsley; B Lohkamp; W G Scott; K Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-03-24

Review 6.  The nature of dominant mutations of rhodopsin and implications for gene therapy.

Authors:  John H Wilson; Theodore G Wensel
Journal:  Mol Neurobiol       Date:  2003-10       Impact factor: 5.590

7.  Hemoglobin S Antilles: a variant with lower solubility than hemoglobin S and producing sickle cell disease in heterozygotes.

Authors:  N Monplaisir; G Merault; C Poyart; M D Rhoda; C Craescu; M Vidaud; F Galacteros; Y Blouquit; J Rosa
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

8.  Impact of retinal disease-associated RPE65 mutations on retinoid isomerization.

Authors:  Grzegorz Bereta; Philip D Kiser; Marcin Golczak; Wenyu Sun; Elise Heon; David A Saperstein; Krzysztof Palczewski
Journal:  Biochemistry       Date:  2008-08-23       Impact factor: 3.162

9.  Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega.

Authors:  Fabian Sievers; Andreas Wilm; David Dineen; Toby J Gibson; Kevin Karplus; Weizhong Li; Rodrigo Lopez; Hamish McWilliam; Michael Remmert; Johannes Söding; Julie D Thompson; Desmond G Higgins
Journal:  Mol Syst Biol       Date:  2011-10-11       Impact factor: 11.429

10.  The clinical features of retinal disease due to a dominant mutation in RPE65.

Authors:  Sarah Hull; Rajarshi Mukherjee; Graham E Holder; Anthony T Moore; Andrew R Webster
Journal:  Mol Vis       Date:  2016-06-10       Impact factor: 2.367

View more
  15 in total

1.  Evidence for distinct rate-limiting steps in the cleavage of alkenes by carotenoid cleavage dioxygenases.

Authors:  Nimesh Khadka; Erik R Farquhar; Hannah E Hill; Wuxian Shi; Johannes von Lintig; Philip D Kiser
Journal:  J Biol Chem       Date:  2019-05-28       Impact factor: 5.157

2.  Aberrant RNA splicing is the major pathogenic effect in a knock-in mouse model of the dominantly inherited c.1430A>G human RPE65 mutation.

Authors:  Yan Li; Rachel Furhang; Amanda Ray; Todd Duncan; Joseph Soucy; Rashid Mahdi; Vijender Chaitankar; Linn Gieser; Eugenia Poliakov; Haohua Qian; Pinghu Liu; Lijin Dong; Igor B Rogozin; T Michael Redmond
Journal:  Hum Mutat       Date:  2019-01-25       Impact factor: 4.878

3.  A large animal model of RDH5-associated retinopathy recapitulates important features of the human phenotype.

Authors:  Laurence M Occelli; Anahita Daruwalla; Samantha R De Silva; Paige A Winkler; Kelian Sun; Nathaniel Pasmanter; Andrea Minella; Janice Querubin; Leslie A Lyons; Anthony G Robson; Elise Heon; Michel Michaelides; Andrew R Webster; Krzysztof Palczewski; Ajoy Vincent; Omar A Mahroo; Philip D Kiser; Simon M Petersen-Jones
Journal:  Hum Mol Genet       Date:  2022-04-22       Impact factor: 5.121

Review 4.  Clinical Perspective: Treating RPE65-Associated Retinal Dystrophy.

Authors:  Albert M Maguire; Jean Bennett; Elena M Aleman; Bart P Leroy; Tomas S Aleman
Journal:  Mol Ther       Date:  2020-12-03       Impact factor: 11.454

Review 5.  Retinal pigment epithelium 65 kDa protein (RPE65): An update.

Authors:  Philip D Kiser
Journal:  Prog Retin Eye Res       Date:  2021-10-02       Impact factor: 19.704

6.  Preparation and characterization of metal-substituted carotenoid cleavage oxygenases.

Authors:  Xuewu Sui; Erik R Farquhar; Hannah E Hill; Johannes von Lintig; Wuxian Shi; Philip D Kiser
Journal:  J Biol Inorg Chem       Date:  2018-06-26       Impact factor: 3.358

7.  Advanced late-onset retinitis pigmentosa with dominant-acting D477G RPE65 mutation is responsive to oral synthetic retinoid therapy.

Authors:  Paul F Kenna; Marian M Humphries; Anna-Sophia Kiang; Philippe Brabet; Laurent Guillou; Ema Ozaki; Matthew Campbell; G Jane Farrar; Robert Koenekoop; Pete Humphries
Journal:  BMJ Open Ophthalmol       Date:  2020-05-05

8.  Pathogenicity Reclasssification of RPE65 Missense Variants Related to Leber Congenital Amaurosis and Early-Onset Retinal Dystrophy.

Authors:  Fabiana L Motta; Renan P Martin; Fernanda B O Porto; Elizabeth S Wohler; Rosane G Resende; Caio P Gomes; João B Pesquero; Juliana M F Sallum
Journal:  Genes (Basel)       Date:  2019-12-24       Impact factor: 4.096

9.  Phenotypic expansion of autosomal dominant retinitis pigmentosa associated with the D477G mutation in RPE65.

Authors:  Ruben Jauregui; Ahra Cho; Jin Kyun Oh; Akemi J Tanaka; Janet R Sparrow; Stephen H Tsang
Journal:  Cold Spring Harb Mol Case Stud       Date:  2020-02-03

Review 10.  Mouse Models of Inherited Retinal Degeneration with Photoreceptor Cell Loss.

Authors:  Gayle B Collin; Navdeep Gogna; Bo Chang; Nattaya Damkham; Jai Pinkney; Lillian F Hyde; Lisa Stone; Jürgen K Naggert; Patsy M Nishina; Mark P Krebs
Journal:  Cells       Date:  2020-04-10       Impact factor: 7.666

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.